NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.

Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C. · 2018

Read NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. by Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5847168.txt.

Introduction

Böttcher and co-authors show that natural killer cells call in the dendritic cells tumors fear most. Their study appeared in Cell. Type 1 conventional dendritic cells spark antitumor immunity. Their numbers inside tumors predict rejection and therapy success.

In mouse tumors, those dendritic cells arrive only when NK cells beckon. The NK cells release two attractants, CCL5 and XCL1. Human cancers rich in both signals hold more of the pair and fare better. Tumors fight back with prostaglandin E2. It saps NK cells and blinds the dendritic cells to the call. Blocking that sabotage could aid immunotherapy.

Catalog record

CREATORBöttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE86 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5847168

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control By Jan P Böttcher, Eduardo Bonavita, Probir Chakravarty, Hanna Blees, Mar Cabeza-Cabrerizo, Stefano Sammicheli, Neil C Rogers, Erik Sahai, Santiago Zelenay, Caetano Reis e Sousa Published in: Cell DOI: 10.1016/j.cell.2018.01.004 ABSTRACT Summary Conventional type 1 dendritic cells (cDC1) are critical for antitumor immunity, and their abundance within tumors is associated with immune-mediated rejection and the success of immunotherapy. Here, we show that cDC1 accumulation in mouse tumors often depends on natural killer (NK) cells that produce the cDC1 chemoattractants CCL5 and XCL1. Similarly, in human cancers, intratumoral CCL5, XCL1, and XCL2 transcripts closely correlate with gene signatures of both NK cells and cDC1 and are associated with increased overall patient survival. Notably, tumor production of prostaglandin E2 (PGE2) leads to evasion of the NK cell-cDC1 axis in part by impairing NK cell viability and chemokine production, as well as by causing downregulation of chemokine receptor expression in cDC1. Our findings reveal a cellular and molecular checkpoint for intratumoral cDC1 recruitment that is targeted by tumor-derived PGE2 for immune evasion and that could be exploited for cancer therapy. Keywords: dendritic cells, tumor microenvironment, tumor immune control, cancer immunotherapy, immune evasion INTRODUCTION The tumor microenvironment (TME) contains stromal cells and immune cells that shape cancer development and impact the response to tumor therapy (Hanahan and Weinberg, 2011, Palucka and Coussens, 2016). Intratumoral immune cells comprise lymphocytes, such as T cells, B, cells and natural killer (NK) cells, and diverse populations of myeloid cells, including granulocytes, monocytes, macrophages, and dendritic cells (DCs) (Gajewski et al., 2013, Hanahan and Weinberg, 2011, Palucka and Coussens, 2016). The different myeloid cells within the TME fulfill distinct and sometimes opposing roles. Simplistically, intratumoral monocytes and M2-polarized macrophages can promote cancer cell growth, angiogenesis, and metastasis, as well as contribute to the establishment of an immunosuppressive environment. They are associated with tumor progression and poor clinical outcome (Noy and Pollard, 2014). In contrast, M1-polarized macrophages and DCs contribute to anti-tumor immunity and are associated with a favorable outcome (Engblom et al., 2016). The contribution of conventional DCs (cDCs) to anti-tumor immunity reflects their ability to present tumor antigens and to secrete cytokines that regulate T cell survival and effector function. cDCs can be divided into at least two subsets, conventional type 1 dendritic cells (cDC1) and conventional type 2 dendritic cells (cDC2) (Guilliams et al., 2014, Merad et al., 2013). The cDC1 subset depends for its development on the transcription factor Batf3 and can be identified by the selective expression of the C-type lectin receptor DNGR-1 (aka CLEC9A) and the chemokine receptor XCR1 and, in non-lymphoid organs and in tumors, additional expression of the integrin αE (CD103) in the presence of low expression of CD11b. cDC1 are especially adept at taking up dead tumor cells and transporting tumor antigens to tumor-draining lymph nodes where they constitute the key DC subtype responsible for cross-priming anti-tumor CD8+ T cells (Roberts et al., 2016, Salmon et al., 2016). In addition to this trafficking role, cDC1 also play a key role within tumors themselves. Intratumoral cDC1 attract T cells (Spranger et al., 2017), re-stimulate and expand tumor-specific CD8+ T cells (Broz et al., 2014), and support T cell effector function by secreting interleukin (IL)-12 (Ruffell et al., 2014). The overall importance of cDC1 in anti-tumor immunity is underscored by multiple studies demonstrating that the lack of cDC1 in Batf3−/− mice abolishes the rejection of immunogenic tumors and the response to adoptive T cell therapy and to immune checkpoint blockade (Broz et al., 2014, Hildner et al., 2008, Salmon et al., 2016, Sánchez-Paulete et al., 2016, Spranger et al., 2015). Human cDC1 are very rare within the TME and often excluded from early tumor stages, which might hinder anti-tumor immunity and contribute to cancer progression. Although intratumoral cDC1 have not been investigated in humans in as much detail as in mice, cDC1 abundance in human melanoma correlates with T cell infiltration and the ratio of cDC1-selective transcripts over macrophage-restricted transcripts can be used as a prognostic marker for cancer patient survival (Broz et al., 2014, Spranger et al., 2017). Therapies aimed at increasing cDC1 abundance in tumors or facilitating their activation may therefore boost anti-tumor immunity and potentially increase the responsiveness of cancer patients to immunotherapy (Broz et al., 2014, Salmon et al., 2016, Spranger et al., 2017). However, the mechanisms determining the abundance of cDC1 at the tumor site remain enigmatic and it is unclear whether cDC1 are actively recruited into the TME and if this requires the participation of other cell types. Prostaglandin E2 (PGE2) is a prostanoid with immune-regulatory function that is produced by many cell types and can further be released upon cell death (Hangai et al., 2016). We previously found that many tumors secrete PGE2 to suppress anti-cancer immunity (Zelenay et al., 2015). In such tumors, genetic ablation of cyclooxygenases, encoded by the Ptgs1 and Ptgs2 genes, leads to inability to produce PGE2 and renders the cancers susceptible to cDC1-dependent CD8+ T cell-mediated immune control (Zelenay et al., 2015). Mouse tumors lacking PGE2 production are therefore an ideal system in which to dissect the mechanisms underlying cDC1 accumulation. Here, we show that such tumors are infiltrated by cDC1, and we identify a key role for intratumoral NK cells in producing CCL5 and XCL1 chemokines that promote cDC1 recruitment. We provide evidence that a similar NK cell/chemokine functional axis determines cDC1 abundance in human melanoma, breast cancer, lung cancer, and head and neck squamous cell carcinoma and show that it impacts on patient survival. Finally, we uncover a role for PGE2 both in diminishing NK cell survival and function and in downregulating cDC1 responsiveness to chemoattractants. These data provide insights into the control of cDC1 accumulation in tumors in mice and humans and support the rational design of therapies aiming to increase cDC1 numbers in tumors that might help overcoming resistance to current immunotherapies. RESULTS cDC1 Accumulate within the Tumor Microenvironment of COX-Deficient Tumors We established a flow cytometry staining protocol that allows distinction between cDC1 and other CD11c+MHC class II (MHCII)+ myeloid cell populations including CD64+ macrophages and CD11b+ cDC2 in tumors (Figure 1A). CD103+ but not other cells (putative cDC2) among CD64−CD11c+MHCII+ cells expressed DNGR-1 (Sancho et al., 2008), XCR1 (Dorner et al., 2009), and IRF8 (Ginhoux et al., 2009) (Figure 1B), validating them as bona fide cDC1. We used the staining protocol to assess cDC1 abundance in PGE2-producing control (COX-competent) BRAFV600E and Ptgs1/Ptgs2−/− (COX-deficient) BRAFV600E melanoma tumors (Zelenay et al., 2015). We focused initial analyses on 4 days after tumor cell implantation, before the onset of any T cell-mediated immune control of the COX-deficient tumors (Zelenay et al., 2015). As reported (Zelenay et al., 2015), control and Ptgs1/Ptgs2−/− BRAFV600E tumors were broadly equivalent in terms of total number of CD45+ cells, CD11c+MHCII+ cells, and tumor mass (Figure 1C). However, Ptgs1/Ptgs2−/− BRAFV600E showed markedly greater accumulation of cDC1, both in frequency and in total numbers (Figure 1C) (Zelenay et al., 2015). Consistent with the flow cytometric analysis, cDC1 were sparse in confocal images of sections from control BRAFV600E tumors but abundant in those from Ptgs1/Ptgs2−/− BRAFV600E tumors (Figures 1D and 1E). In addition

Read the complete text